Literature DB >> 18288975

PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples.

Malin Holm1, Frank Olav Pettersen, Dag Kvale.   

Abstract

The immunopathogenic factor programmed cell death 1 (PD-1) was compared to CD38 and HIV RNA in predicting actual CD4+ T cell loss rate indicative for clinical progression. This cross sectional exploratory study included 50 consecutive, healthy HIV-infected patients off antiretroviral therapy (ART); 43 had the required observation times > 12 months. PD-1 and CD38 were determined on various T cell subsets by FACS analyses in fresh and later in parallel cryopreserved samples. Here more rapid progressors were relatively defined by having CD4 loss rates < median at -45.7/microl/year. PD-1 and CD38 densities in fresh blood were lower (p<0.001) in patients on ART (n=14) and seronegative controls (n=8). CD4 loss rates correlated significantly to current HIV RNA (R=-0.30), CD38 (R=-0.33) and PD-1 densities (R=-0.38) on CD8+ T cells, and best to DeltaCD38, i.e. the difference in CD38 between the PD-1+CD8+ and CD8+ subsets (R=-0.51). PD-1 was highest on the CD27+CD28-CD8+ subset with best correlation to progression (R=-0.54) in rapid progressors. Logistic regression models from HIV RNA, CD38 and PD-1 predicting rapid progression included PD-1 as best independent variable in combination with DeltaCD38 or CD38, supported by similar results from multiple regression analyses. PD-1 did not correlate with any of the other candidate variables. Cryopreservation reduced the CD38+ and PD-1+ fractions but corresponding densities became more suppressed through a non-linear loss most pronounced in CD38hi/PD-1hi cells with loss of predictive power. In conclusion, PD-1 was the best independent predictor for CD4 loss rates in fresh blood compared with CD38 and HIV RNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288975     DOI: 10.2174/157016208783571955

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  10 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Authors:  Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 4.  Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease.

Authors:  Pratip K Chattopadhyay; Mario Roederer
Journal:  Cytometry A       Date:  2010-07       Impact factor: 4.355

5.  Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.

Authors:  F O Pettersen; K Taskén; D Kvale
Journal:  Clin Exp Immunol       Date:  2010-05-10       Impact factor: 4.330

6.  Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Authors:  Florin Tuluc; Sergei Spitsin; Nancy B Tustin; Jennifer B Murray; Richard Tustin; Laura A Schankel; Andrew Wiznia; Sharon Nachman; Steven D Douglas
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-18       Impact factor: 2.205

7.  Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes.

Authors:  D E Campbell; N B Tustin; E Riedel; R Tustin; J Taylor; J Murray; S D Douglas
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

8.  HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008.

Authors:  Hans-Jürgen Stellbrink; S Baldus; G Behrens; J R Bogner; T Harrer; C Hoffmann; J van Lunzen; J Münch; P Racz; C Scheller; M Stoll; K Tenner-Racz; J Rockstroh
Journal:  Eur J Med Res       Date:  2010-01-29       Impact factor: 2.175

9.  A parameter for IL-10 and TGF-ß mediated regulation of HIV-1 specific T cell activation provides novel information and relates to progression markers.

Authors:  Andreas Lind; Kristin Brekke; Frank Olav Pettersen; Tom Eirik Mollnes; Marius Trøseid; Dag Kvale
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

10.  Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Authors:  Pablo Tebas; Sergei Spitsin; Jeffrey S Barrett; Florin Tuluc; Okan Elci; James J Korelitz; Wayne Wagner; Angela Winters; Deborah Kim; Renae Catalano; Dwight L Evans; Steven D Douglas
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.